التفاصيل البيبلوغرافية
| العنوان: |
Prognostic value of high-sensitivity C-reactive protein among chronic kidney disease patients undergoing percutaneous coronary intervention. |
| المؤلفون: |
Jones, Davis, Spirito, Alessandro, Sartori, Samantha, Smith, Kenneth F., Pivato, Carlo Andrea, Chiarito, Mauro, Cao, Davide, Nicolas, Johny, Beerkens, Frans, Edens, Madison, Pileggi, Brunna, Sen, Ananya, Zhang, Zhongjie, Vogel, Birgit, Sweeny, Joseph, Baber, Usman, Dangas, George, Sharma, Samin K., Kini, Annapoorna, Mehran, Roxana |
| المصدر: |
Journal of Cardiology; Sep2023, Vol. 82 Issue 3, p179-185, 7p |
| مستخلص: |
Data on the prognostic value of high-sensitivity C-reactive protein (hs-CRP) levels in patients with chronic kidney disease (CKD) undergoing percutaneous coronary intervention (PCI) are limited. Patients undergoing PCI at a tertiary center from January 2012 to December 2019 were included. CKD was defined as a glomerular filtration rate (GFR) <60 mL/min/1.73m2 and elevated hs-CRP was defined as >3 mg/L. Acute myocardial infarction (MI), acute heart failure, neoplastic disease, patients undergoing hemodialysis, or hs-CRP >10 mg/L were exclusion criteria. The primary outcome was major adverse cardiac events (MACE), a composite of all-cause death, MI, and target vessel revascularization at 1-year after PCI. Out of 12,410 patients, 3029 (24.4 %) had CKD. Elevated hs-CRP levels were found in 31.8 % of CKD and 25.8 % of no-CKD patients. At 1 year, MACE occurred in 87 (11.0 %) CKD patients with elevated hs-CRP and 163 (9.5 %) with low hs-CRP (adj. HR 1.26, 95 % CI 0.94–1.68); among no-CKD patients, in 200 (10 %) and 470 (8.1 %), respectively (adj. HR 1.21, 95 % CI 1.00–1.45). Hs-CRP was associated with an increased risk of all-cause death in both CKD (Adj. HR 1.92, 95 % CI 1.07–3.44) and no-CKD patients (adj. HR 3.02, 95 % CI 1.74–5.22). There was no interaction between hs-CRP and CKD status. Among patients undergoing PCI without acute MI, elevated hs-CRP values were not associated with a higher risk of MACE at 1 year, but with increased mortality hazards consistently in patients with or without CKD. [Display omitted] • The role of high-sensitivity C-reactive protein (hs-CRP) in percutaneous coronary intervention (PCI) is still uncertain. • In a large PCI registry, 25% of patients had chronic kidney disease (CKD) and about 27% had elevated hs-CRP • Elevated hs-CRP was not associated with higher risk of major adverse cardiac events at 1 year • Elevated hs-CRP was an independent predictor of all-cause death at 1 year • These results were consistent in patients with or without CKD [ABSTRACT FROM AUTHOR] |
|
Copyright of Journal of Cardiology is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Supplemental Index |
